Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor

References

• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.
   PubMed Web of Science ®Google Scholar
• Keller L, Belloum Y, Wikman H, et al. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br J Cancer. 2021;124(2):345–358.
   PubMed Web of Science ®Google Scholar
• Kilgour E, Rothwell DG, Brady G, et al. Liquid Biopsy-Based biomarkers of treatment response and resistance. Cancer Cell. 2020;37(4):485–495.
   PubMed Web of Science ®Google Scholar
• Gray ES, Rizos H, Reid AL, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015;6(39):42008–42018.
   PubMedGoogle Scholar
• Dasari A, Morris VK, Allegra CJ, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and rectal–anal task forces whitepaper. Nat Rev Clin Oncol. 2020;17(12):757–770.
   PubMed Web of Science ®Google Scholar
• Dawson S-J, Tsui DWY, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13):1199–1209.
   PubMed Web of Science ®Google Scholar
• Cancer genome atlas network. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681–1696.
   PubMed Web of Science ®Google Scholar
• Ny L, Hernberg M, Nyakas M, et al. BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis. Acta Oncol. 2020;59(7):833–844.
   PubMed Web of Science ®Google Scholar
• Lee J-H, Choi J-W, Kim Y-S. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol. 2011;164(4):776–784.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Minor D, Ribas A, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 2013;31(26):3205–3211.
   PubMed Web of Science ®Google Scholar
• Santiago-Walker A, Gagnon R, Mazumdar J, et al. Correlation of BRAF mutation status in Circulating-Free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clin Cancer Res. 2016;22(3):567–574.
   PubMed Web of Science ®Google Scholar
• Seremet T, Jansen Y, Planken S, et al. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. J Transl Med. 2019;17(1):303.
   PubMed Web of Science ®Google Scholar
• Syeda MM, Wiggins JM, Corless BC, et al. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. Lancet Oncol. 2021;22(3):370–380.
   PubMed Web of Science ®Google Scholar
• Rowe SP, Luber B, Makell M, et al. From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting. Mol Oncol. 2018;12(10):1661–1672.
   PubMed Web of Science ®Google Scholar
• Lee RJ, Gremel G, Marshall A, et al. Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma. Ann Oncol. 2018;29(2):490–496.
   PubMed Web of Science ®Google Scholar
• Tan L, Sandhu S, Lee RJ, et al. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann Oncol. 2019;30(5):804–814.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cao M, Mayo-de-Las-Casas C, Molina-Vila MA, et al. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Melanoma Res. 2015;25(6):486–495.
   Google Scholar
• BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Melanoma Res. 2015;25(6):486–495.
   PubMed Web of Science ®Google Scholar
• Váraljai R, Wistuba-Hamprecht K, Seremet T, et al. Application of circulating Cell-Free tumor DNA profiles for therapeutic monitoring and outcome prediction in genetically heterogeneous metastatic melanoma. J Clin Oncol Precis Oncol. 2019;3(3):1–10.
   Google Scholar
• McEvoy AC, Warburton L, Al-Ogaili Z, et al. Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC Cancer. 2018;18(1):726.
   PubMed Web of Science ®Google Scholar
• Lee JH, Long GV, Boyd S, et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol. 2017;28(5):1130–1136.
   PubMed Web of Science ®Google Scholar
• Forthun RB, Hovland R, Schuster C, et al. ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. Sci Rep. 2019;9(1):17471.
   PubMed Web of Science ®Google Scholar
• Seremet T, Planken S, Schreuer M, et al. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy. Melanoma Res. 2018;28(1):65–70.
   PubMed Web of Science ®Google Scholar
• Mattila KE, Vihinen P, Ramadan S, et al. Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma. Acta Oncol. 2020;59(3):310–314.
   PubMed Web of Science ®Google Scholar
• Holm M, Andersson E, Osterlund E, et al. Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, idylla, and next generation sequencing. PLoS One. 2020;15(11):e0239819.
   PubMed Web of Science ®Google Scholar
• Long GV, Grob J-J, Nathan P, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016;17(12):1743–1754.
   PubMed Web of Science ®Google Scholar
• Weide B, Martens A, Hassel JC, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 2016;22(22):5487–5496.
   PubMed Web of Science ®Google Scholar
• Iivanainen S, Ahvonen J, Knuuttila A, et al. Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors. ESMO Open. 2019;4(4):e000531.
   PubMed Web of Science ®Google Scholar
• Ny L, Jespersen H, Karlsson J, et al. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. Nat Commun. 2021;12(1):5155.
   PubMed Web of Science ®Google Scholar